Onkologie. 2021:15(3):136-138 | DOI: 10.36290/xon.2021.026
Vismodegib in treatment of reccurence, locally advanced basal cell carcinoma
- Kožní oddělení LF OU a FN Ostrava
Basal cell carcinoma is the most common form of nonmelanoma skin cancer that arises from basal cells, characterized by slow and destruct growth. The most often terapeutic option is surgical excision. Other options include radiotherapy, application of imiquimod, 5-fluoruracil, curettage, electrocautery, cryotherapy, laser ablation, photodynamic therapy and systemic therapy by the hedgehog inhibitors. Case report describe male patient with recurrent infiltrative basal cell carcinoma located at the forehead on the right, treated by surgical excision, radiotherapy and targeted systemic therapy - vismodegib.
Keywords: vismodegib, basal cell carcinoma, hedgehog signaling pathway.
Published: May 6, 2021 Show citation
References
- Ciążyńska M, Narbutt J, Woźniacka A, et al. Trends in basal cell carcinoma incidence rates: a 16-year retrospective study of a population in central Poland. Postepy Dermatol. Alergol 2018; 35(1): 47-52.
Go to original source... 
Go to PubMed... - Peterson SC, Eberk M, Vagnozzi AN, et al. Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niches. Cell Stem Cell 2015; 16(4): 400-412. Go to original source... Go to PubMed...
- Mackiewicz-Wysocka M, Bowszyc-Dmochowska M, Strzelecka-Węklar D, et al, Basal cell carcinoma - diagnosis. Contemp Oncol 2013; 17(4): 337-342. Go to original source... Go to PubMed...
- Migden MR, Chang ALS, Dirix L, et al. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treatment Reviews 2018; 64: 1-10. Go to original source... Go to PubMed...
- Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus - based interdisciplinary guidelines. European Journal of cancer 2019; 118: 10-34. Go to original source... Go to PubMed...
- Krajsová I. Vismodegib - cílená léčba inoperabilního bazocelulárního karcinomu. Remedia online 2014; 4: 321-324.
- Axelson M, Liu K, Jiang X, et al. U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma. American Association for Cancer Research. Clin Cancer Res 2013; 19: 2289-2293. Go to original source... Go to PubMed...
- Athar M, Tang X, Lee JL, et al. Hedgehog signalling in skin development and cancer. Experimental dermatology 2006; 9: 667-677. Go to original source... Go to PubMed...